ArticleCardiovascular therapeutics2023
The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients.
Article in Cardiovascular therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Effects of GLP-1 Receptor Agonists on Psoriasis: An "Agent-Specific" Systematic Review of the Literature.Journal of clinical medicine · 2026Review
- Exploration of the Effects of SGLT-2 Inhibitors and GLP-1 Receptor Agonists on Coronary Inflammation in Type 2 Diabetes Patients Based on the Peri-Coronary Fat Attenuation Index.Reviews in cardiovascular medicine · 2026Article
- Coronary computed tomography angiography adipose tissue attenuation in diabetic patients with myocardial ischemia and non-obstructive coronary arteries.World journal of cardiology · 2026Article
- High-intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus.Diabetes, obesity & metabolism · 2025Article
- Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Association between epicardial adipose tissue imaging characteristics and left atrial appendage thrombus in patients with atrial fibrillation.International journal of cardiology. Heart & vasculature · 2025Article
- Computed tomography-based assessment of pericoronary adipose tissue in cardiovascular diseases: Diagnostic and prognostic implications.World journal of radiology · 2025Review
- Coronary inflammation and atherosclerosis by CCTA in young adults (aged 18-45).American journal of preventive cardiology · 2025Article
- Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation.Cardiovascular diabetology · 2024Observational
- Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes.Endocrinology, diabetes & metabolism case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular inflammation can be detected in the pericoronary adipose tissue (PCAT) by coronary computed tomography angiography (CCTA) attenuation. Treatment with liraglutide is associated with anti-inflammatory effects and reduces cardiovascular risk in diabetic patients. This study is aimed at examining the effect of clinically indicated liraglutide on PCAT attenuation. Asymptomatic patients with type 2 diabetes mellitus (T2DM) and without known ischemic heart disease underwent clinical examination, blood analysis, and CCTA. The main coronary arteries were outlined and PCAT attenuation was measured on the proximal 40 mm. Patients treated with liraglutide on a clinical indication were compared to patients not receiving liraglutide. The study included 190 patients; 53 (28%) received liraglutide (Lira+) and 137 (72%) did not (Lira-). There were no significant differences in PCAT attenuation between the two groups in either artery. However, PCAT attenuation measured around the left anterior descending artery (LAD) was lower in the Lira+ group after adjustment for age, sex, body mass index, and T2DM duration (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.